Hematologic Malignancy
T Lymphoblastic Lymphoma
CI-CAN-00004058Explore in graph →
Hematologic11 active trials
- NCIt
- C6919
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004058Explore in graph →
Clinical trials
26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04315324 | Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | active not recruiting | Phase 1 / Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 |
| clinicaltrials |
| NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | not yet recruiting | Phase 2 / Phase 3 | 1,708 | Children's Oncology GroupNETWORK | 0 | Jul 30, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT00408005 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 3 | 1,895 | National Cancer Institute (NCI)NIH | 5 | Jun 23, 2026 | clinicaltrials |
| NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies(ADAPT-HEM) | recruiting | Phase 1 / Phase 2 | 96 | Beijing BiotechINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT06741813 | Allo-HSCT vs ASCT in Adult T-LBL(TROPHY-NHL01) | not yet recruiting | N/A | 230 | Peking University People's HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06434467 | The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma | unknown | Phase 3 | 83 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04582487 | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL | unknown | N/A | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | suspended | Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | recruiting | Phase 1 | 9 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | terminated | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT04620655 | RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL | unknown | N/A | 24 | Min XiangOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04004637 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT01363817 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 1 | 31 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03558412 | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma | unknown | Phase 4 | 40 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials